Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CERT logo CERT
Upturn stock ratingUpturn stock rating
CERT logo

Certara Inc (CERT)

Upturn stock ratingUpturn stock rating
$11.7
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CERT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $15.78

1 Year Target Price $15.78

Analysts Price Target For last 52 week
$15.78Target price
Low$8.63
Current$11.7
high$16.93

Analysis of Past Performance

Type Stock
Historic Profit -5.21%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.85B USD
Price to earnings Ratio -
1Y Target Price 15.78
Price to earnings Ratio -
1Y Target Price 15.78
Volume (30-day avg) 11
Beta 1.45
52 Weeks Range 8.63 - 16.93
Updated Date 06/30/2025
52 Weeks Range 8.63 - 16.93
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.02

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -0.67%
Operating Margin (TTM) 7.19%

Management Effectiveness

Return on Assets (TTM) 1.12%
Return on Equity (TTM) -0.25%

Valuation

Trailing PE -
Forward PE 24.88
Enterprise Value 1971766962
Price to Sales(TTM) 4.68
Enterprise Value 1971766962
Price to Sales(TTM) 4.68
Enterprise Value to Revenue 5
Enterprise Value to EBITDA 23.59
Shares Outstanding 162234000
Shares Floating 121837605
Shares Outstanding 162234000
Shares Floating 121837605
Percent Insiders 2.48
Percent Institutions 100.81

Analyst Ratings

Rating 4
Target Price 15.78
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold 6
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Certara Inc

stock logo

Company Overview

overview logo History and Background

Certara, Inc. was founded in 2008 through the merger of several leading biosimulation companies. It focuses on biosimulation software and services to improve drug development and regulatory science. The company went public in December 2020.

business area logo Core Business Areas

  • Model-Informed Drug Development (MIDD): This segment provides software and services that use biosimulation and data analytics to optimize drug development processes, predict clinical trial outcomes, and support regulatory submissions.
  • Integrated Drug Development: This segment offers a suite of services to help biotech, pharma and biosimilar companies de-risk their investment decisions and maximize product opportunities.

leadership logo Leadership and Structure

Certara is led by CEO William F. Feehery. The organizational structure includes various functional departments such as R&D, sales, marketing, finance, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Simcyp: A physiologically based pharmacokinetic (PBPK) modeling and simulation platform used to predict drug behavior in different populations and inform clinical trial design. Competitors include Open Systems Pharmacology (NONMEM, Monolix) and academic institutions. Market share is estimated to be significant within the PBPK modeling market.
  • Phoenix: A pharmacokinetic and pharmacodynamic (PK/PD) modeling and analysis software platform used for data analysis, non-compartmental analysis, and population PK/PD modeling. Competitors include NONMEM and R. Market share is also considerable within its target market.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry faces increasing pressures to reduce drug development costs and timelines. Regulatory agencies are also encouraging the use of model-informed drug development (MIDD) approaches. The market for biosimulation software and services is growing.

Positioning

Certara is a leading provider of biosimulation software and services. Its competitive advantages include a comprehensive product portfolio, deep domain expertise, and a strong track record of successful regulatory submissions.

Total Addressable Market (TAM)

The total addressable market for biosimulation is estimated to be several billion USD. Certara is well-positioned to capture a significant share of this market given its extensive capabilities.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition
  • Comprehensive product portfolio
  • Deep domain expertise
  • Global presence
  • Long-standing relationships with regulatory agencies

Weaknesses

  • Dependence on the biopharmaceutical industry
  • Relatively high price point
  • Complexity of software requires specialized training

Opportunities

  • Increasing adoption of MIDD by regulatory agencies
  • Expansion into new therapeutic areas
  • Growth in emerging markets
  • Integration of artificial intelligence and machine learning into biosimulation
  • Increasing use of real world evidence (RWE) in drug development

Threats

  • Competition from other biosimulation vendors
  • Economic downturn affecting biopharmaceutical R&D spending
  • Regulatory changes
  • Open-source alternatives
  • Data privacy and security concerns

Competitors and Market Share

competitor logo Key Competitors

  • Certara(CERT)
  • Simulations Plus (SLP)
  • Dassault Systemes (DSY.PA)

Competitive Landscape

Certara has advantages in its comprehensive product portfolio and deep domain expertise. Competitors may have strengths in specific areas such as specialized software or broader life sciences solutions.

Major Acquisitions

Pinnacle 21

  • Year: 2020
  • Acquisition Price (USD millions): 200
  • Strategic Rationale: Expanded its data analysis and regulatory submission capabilities

Growth Trajectory and Initiatives

Historical Growth: Certara's historical growth has been driven by increasing demand for biosimulation software and services. Growth will be filled in with the past year's revenue growth from latest reports.

Future Projections: Future growth is projected to be driven by continued adoption of MIDD, expansion into new markets, and strategic acquisitions. This growth has been discussed at various conference calls and will be filled in when data is available.

Recent Initiatives: Recent strategic initiatives include acquisitions of companies to expand product offerings, partnerships with biopharmaceutical companies, and investments in R&D.

Summary

Certara is a key player in biosimulation with a strong product portfolio and expertise, benefiting from increased MIDD adoption. While facing competition and industry dependence, it has growth opportunities through market expansion and AI integration. Certara's strategic acquisitions and collaborations further strengthen its position within the biopharmaceutical industry. The company must be vigilant against economic changes and evolving regulatory landscapes to maintain momentum.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Certara Investor Relations
  • SEC Filings
  • Industry Reports
  • Analyst Estimates

Disclaimers:

This analysis is based on available information and estimates. Actual results may vary. This is not financial advice. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Certara Inc

Exchange NASDAQ
Headquaters Radnor, PA, United States
IPO Launch date 2020-12-11
CEO & Director Dr. William F. Feehery Ph.D.
Sector Healthcare
Industry Health Information Services
Full time employees 1487
Full time employees 1487

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I